This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1025 entries already.
Belgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.
Not the German InFamily Foods subsidiary The Cultivated B, but Gourmey SAS, founded in Paris in 2019 by Antoine Davydoff, Nicolas Morin-Forest and Victor Sayous, has submitted the first EU authorisation application for a cell-based meat product, a duck liver pâté (Foie gras), to the European Food Safety Authority (EFSA).
Swiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
A research consortium led by Charité in Berlin has found a protein pattern in 100 patients with the common blood cancer multiple myeloma and 38 healthy controls that independently identifies a poor prognosis and provides new targets for treating the incurable disease.
Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Scientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
In view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Czech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Targeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.